# US 2026/0091133 A1 · Rod-derived cone viability factor fusion protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091133 A1
- Document ID: US20260091133A1
- Status: Published application
- Kind: A1
- Application number: 19/339,969
- Filed: 2025-09-25
- Published: 2026-04-02
- Earliest claimed: 2024-09-27
- Assignees: Pharma Cinq, LLC
- Applicants: Pharma Cinq, LLC
- Inventors: Tianci LUO; Daniel LIPUT; Fong Qi LIANG
- Web page: https://patentgrep.com/patent/US20260091133A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 14/475: Growth factors; Growth regulators
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 27/02: Ophthalmic agents
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a fusion protein comprising a) a short rod-derived cone viability factor (RdCVF-S), b) a hydrophilic peptide, and c) a signal peptide, along with the nucleic acids encoding those peptides and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting the fusion protein comprising RdCVF-S protein, an immunoglobulin constant region, and a human signal sequence, and methods of treatment.

## Claims

### Claim 1

A fusion protein comprising a first N-terminal signal peptide, a second peptide C-terminal to the signal peptide, and a third peptide C-terminal to the second peptide;
wherein the second peptide or the third peptide is an RdCVF-short peptide and the other is an immunoglobulin constant region.

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein the second peptide is an RdCVF-short peptide, and the third peptide sequence is an immunoglobulin constant region.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein the second peptide is an immunoglobulin constant region, and the third peptide is an RdCVF-short peptide.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein the signal peptide is a human signal peptide.

### Claim 5 (depends on 1)

The fusion protein of claim 1, wherein the signal peptide is an immunoglobulin kappa chain (Igk) signal peptide, a human growth hormone (HGH), a brain-derived neurotrophic factor (BDNF), an insulin growth factor 1 (IGF-1), a β-glucuronidase (GUSB), or an albumin signal peptide.

### Claim at position 6

6-34. (canceled)

### Claim 35

A nucleic acid comprising a nucleotide sequence encoding a fusion protein comprising a first N-terminal signal peptide, a second peptide C-terminal to the signal peptide, and a third peptide C-terminal to the second peptide sequence;
wherein the second peptide or the third peptide sequence is an RdCVF-short peptide sequence and the other is an immunoglobulin constant region sequence.

### Claim at position 8

36-71. (canceled)

### Claim 72 (depends on 35)

An expression vector comprising the nucleic acid of claim 35 operatively linked to a control sequence.

### Claim at position 10

73-80. (canceled)

### Claim 81 (depends on 1)

A cell comprising the fusion protein of claim 1;
a nucleic acid comprising a nucleotide sequence encoding the fusion protein; or
an expression vector comprising the nucleic acid operatively linked to a control sequence.

### Claim 82 (depends on 1)

A pharmaceutical composition comprising: (i) the fusion protein of claim 1;
a nucleic acid comprising a nucleotide sequence encoding the fusion protein;
an expression vector comprising the nucleic acid operatively linked to a control sequence; and/or
a cell comprising the fusion protein, the nucleic acid, or the expression vector;
and (ii) a pharmaceutically acceptable carrier.

### Claim 83 (depends on 1)

A method for treating a condition in a mammalian subject in need thereof, comprising administering to the subject an effective amount of the fusion protein of claim 1;
a nucleic acid comprising a nucleotide sequence encoding the fusion protein;
an expression vector comprising the nucleic acid operatively linked to a control sequence;
a cell comprising the fusion protein, the nucleic acid, or the expression vector; and/or
a pharmaceutical composition comprising the fusion protein, the nucleic acid, the expression vector, or the cell, thereby treating the condition in the subject.

### Claim at position 14

84-85. (canceled)

### Claim 86 (depends on 1)

A method of protecting ocular photoreceptor cells in a subject in need thereof, comprising administering to an eye of the subject an effective amount of the fusion protein of claim 1;
a nucleic acid comprising a nucleotide sequence encoding the fusion protein;
an expression vector comprising the nucleic acid operatively linked to a control sequence;
a cell comprising the fusion protein, the nucleic acid, or the expression vector; and/or
a pharmaceutical composition comprising the fusion protein, the nucleic acid, the expression vector, or the cell, thereby protecting the ocular photoreceptor cells in the subject.

### Claim at position 16

87-88. (canceled)

### Claim 89 (depends on 1)

A method for producing a fusion protein of claim 1, comprising culturing cell comprising the fusion protein;
a nucleic acid comprising a nucleotide sequence encoding the fusion protein; or
an expression vector comprising the nucleic acid operatively linked to a control sequence, under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.

### Claim 90

A fusion protein comprising a first N-terminal signal peptide, a second peptide C-terminal to the signal peptide, and a third peptide C-terminal to the second peptide;
wherein the first peptide is a human immunoglobulin kappa chain (Igk) signal sequence; and
wherein the second peptide or the third peptide is an RdCVF-short peptide and the other is a hydrophilic peptide.

### Claim at position 19

91-127. (canceled)

### Claim 128 (depends on 90)

A nucleic acid comprising a nucleotide sequence encoding a fusion protein of claim 90.

### Claim at position 21

129-133. (canceled)

### Claim 134 (depends on 128)

An expression vector comprising the nucleic acid of claim 128, operatively linked to a control sequence.

### Claim at position 23

135-142. (canceled)

### Claim 143 (depends on 90)

A cell comprising the fusion protein of claim 90; a nucleic acid comprising a nucleotide sequence encoding the fusion protein; or an expression vector encoding the nucleic acid operatively linked to a control sequence.

### Claim 144 (depends on 90)

A pharmaceutical composition comprising: (i) the fusion protein of claim 90;
a nucleic acid comprising a nucleotide sequence encoding the fusion protein;
an expression vector comprising the nucleic acid operatively linked to a control sequence; or
a cell comprising the fusion protein, the nucleic acid, or the expression vector;
and (ii) a pharmaceutically acceptable carrier.

### Claim 145 (depends on 90)

A method for treating a condition in a mammalian subject in need thereof, comprising administering to the subject an effective amount of the fusion protein of claim 90;
a nucleic acid comprising a nucleotide sequence encoding the fusion protein;
an expression vector comprising the nucleic acid operatively linked to a control sequence;
a cell comprising the fusion protein, the nucleic acid, or the expression vector; and/or
a pharmaceutical composition comprising the fusion protein, the nucleic acid, the expression vector, or the cell,
thereby treating the condition in the subject.

### Claim at position 27

146-147. (canceled)

### Claim 148 (depends on 90)

A method of protecting ocular photoreceptor cells in a subject in need thereof, comprising administering to an eye of the subject an effective amount of the fusion protein of claim 90 a nucleic acid comprising a nucleotide sequence encoding the fusion protein;
an expression vector comprising the nucleic acid operatively linked to a control sequence;
a cell comprising the fusion protein, the nucleic acid, or the expression vector; and/or
a pharmaceutical composition comprising the fusion protein, the nucleic acid, the expression vector, or the cell, thereby protecting the ocular photoreceptor cells in the subject.

### Claim at position 29

149-150. (canceled)

### Claim 151 (depends on 90)

A method for producing a fusion protein of claim 90, comprising culturing a cell comprising the fusion protein; a nucleic acid comprising a nucleotide sequence encoding the fusion protein: or an expression vector comprising the nucleic acid operatively linked to a control sequence, under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.
